The 6‐minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study
Muscle & Nerve2013Vol. 48(3), pp. 357–368
Citations Over TimeTop 10% of 2013 papers
Craig M. McDonald, Erik Henricson, Richard T. Abresch, Julaine Florence, Michelle Eagle, Eduard Gappmaier, Allan M. Glanzman, PTC124‐GD‐007‐DMD Study Group, Robert J. Spiegel, Jay Barth, Gary Elfring, Allen Reha, Stuart W. Peltz
Abstract
The ratio of MCID to baseline mean is lower for 6MWD than for other endpoints. The 6MWD is an optimal primary endpoint for Duchenne muscular dystrophy (DMD) clinical trials that are focused therapeutically on preservation of ambulation and slowing of disease progression.
Related Papers
- → Physical Activity in Boys With Duchenne Muscular Dystrophy Is Lower and Less Demanding Compared to Healthy Boys(2017)38 cited
- → Reversal of cardiac and skeletal manifestations of Duchenne muscular dystrophy by cardiosphere-derived cells and their exosomes in mdx dystrophic mice and in human Duchenne cardiomyocytes(2017)9 cited
- → Enhanced urinary spontaneous luminescence in duchenne muscular dystrophy(1994)7 cited
- → VP.85 C-Path's Duchenne Regulatory Science Consortium: Accelerating drug development for Duchenne muscular dystrophy(2022)
- → Design of a phase 2 clinical program for the development of PGN-EDO51 in participants with duchenne muscular dystrophy (DMD)(2023)